肝胆相照论坛

标题: 箭头制药公司报告2017财年年底业绩 [打印本页]

作者: StephenW 时间: 2017-12-13 09:01 标题: 箭头制药公司报告2017财年年底业绩

Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results

- Conference Call and Webcast Today at 4:30 p.m. EST

      PASADENA, Calif.--(BUSINESS WIRE)--    Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial    results for its fiscal 2017 fourth quarter and year ended September 30,    2017. The company is hosting a conference call at 4:30 p.m. EST to    discuss results.
      Conference Call and Webcast Details
      Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm.    For analysts that wish to participate in the conference call, please    dial [url=tel

855)%20215-6159]855-215-6159[/url] or [url=tel

315)%20625-6887]315-625-6887[/url] and provide Conference ID 6977547.
A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial [url=tel

855)%20859-2056]855-859-2056[/url] or [url=tel

404)%20537-3406]404-537-3406[/url] and provide Conference ID 6977547.
Selected Fiscal 2017 and Recent Events

Hosted an Analyst R&D Day in September 2017 to highlight the following:
- The Targeted RNAi Molecule platform, or TRiM™, which utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting, while being structurally simple
- The TRiM™ platform offers several potential competitive advantages including:
  - Simplified manufacturing at reduced cost
  - Multiple routes of administration (subcutaneous, intravenous, and inhaled)
  - Faster time to clinical candidates
  - Wide safety margins
  - Promise of taking RNAi to tissues beyond the liver
- ARO-AAT, Arrowhead's second generation subcutaneously administered clinical candidate for the treatment of alpha-1 antitrypsin deficiency liver disease with a planned Clinical Trial Application (CTA) filing in Q1 2018
- ARO-HBV, Arrowhead's third generation subcutaneously administered clinical candidate for the treatment of chronic hepatitis B virus infection with a planned CTA filing in Q2 2018
- Arrowhead's expanded cardiometabolic pipeline, which now includes ARO-APOC3, targeting apolipoprotein C-III, and ARO-ANG3, targeting angiopoietin-like protein 3 (ANGPTL3) with CTA filings planned around the end of 2018
- The TRiM™ platform's ability to target extra-hepatic tissues, including the lung and tumors, represented by the following programs:
  - ARO-Lung1, the first candidate against an undisclosed gene target in the lung, which achieved almost 90% target knockdown following inhaled administration in rodents
  - ARO-HIF2, Arrowhead's candidate targeting renal cell carcinoma, which achieved 85% target gene knockdown in a rodent tumor model
  - CTA filings are planned in Q4 2018 and in 2019 for ARO-Lung1 and ARO-HIF2, respectively
Presented new clinical data at HEP DART 2017 demonstrating up to 5.0 log10 reduction in HBV s-antigen and a Sustained Host Response in 50% of hepatitis B patients following RNAi therapy, ARC-520, in the 2001 open label extension study
Made continued progress on our two-product cardiovascular collaboration with Amgen, in which one that was previously called ARO-LPA against the target lipoprotein(a) has been formally nominated as a clinical candidate and which is now referred to as AMG-890 by Amgen

Selected Fiscal 2017 Year End Financial Results


ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIAL INFORMATION

	Year Ended September 30,
OPERATING SUMMARY		2017			2016

REVENUE	$	31,407,709		$	158,333
OPERATING EXPENSES
Research and development		31,690,298			41,454,452
Salaries and payroll-related costs		17,292,883			19,461,656
General and administrative expenses		6,838,402			9,940,737
Stock-based compensation		7,891,595			11,595,816
Depreciation and amortization		4,690,440			3,260,045
Impairment expense		-			2,050,817
Contingent consideration - fair value adjustments		-			(5,862,464	)
TOTAL OPERATING EXPENSES		68,403,618			81,901,059
OPERATING LOSS		(36,995,909	)		(81,742,726	)
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES		2,615,614			19,724
NET LOSS	$	(34,380,295	)	$	(81,723,002	)

NET LOSS PER SHARE (BASIC AND DILUTED):	$	(0.47	)	$	(1.34	)
WEIGHTED AVERAGE SHARES OUTSTANDING		73,898,598			61,050,880

FINANCIAL POSITION SUMMARY	September 30,			September 30,
		2017			2016
CASH AND CASH EQUIVALENTS	$	24,838,567		$	85,366,448
SHORT-TERM INVESTMENTS		40,769,539			-
TOTAL CASH RESOURCES (CASH AND INVESTMENTS)		65,608,106			85,366,448
OTHER ASSETS		38,414,174			42,810,057
TOTAL ASSETS		104,022,280			128,176,505
TOTAL LIABILITIES		23,155,118			33,152,246
TOTAL STOCKHOLDERS' EQUITY		80,867,162			95,024,259
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	104,022,280		$	128,176,505

SHARES OUTSTANDING		74,785,426			69,746,685

      About Arrowhead Pharmaceuticals
      Arrowhead Pharmaceuticals develops medicines that treat intractable    diseases by silencing the genes that cause them. Using a broad portfolio    of RNA chemistries and efficient modes of delivery, Arrowhead therapies    trigger the RNA interference mechanism to induce rapid, deep, and    durable knockdown of target genes. RNA interference, or RNAi, is a    mechanism present in living cells that inhibits the expression of a    specific gene, thereby affecting the production of a specific protein.    Arrowhead's RNAi-based therapeutics leverage this natural pathway of    gene silencing.
      For more information, please visit www.arrowheadpharma.com,    or follow us on Twitter @ArrowheadPharma.    To be added to the Company's email list and receive news directly,    please visit http://ir.arrowheadpharma.com/alerts.cfm.

作者: StephenW 时间: 2017-12-13 09:02

箭头制药公司报告2017财年年底业绩

- 电话会议和网络直播今天下午四点三十分美东时间

（Arrowhead Pharmaceuticals，Inc.）（纳斯达克股票代码：ARWR）今天公布了2017财年第四季度财务报告以及截至2017年9月30日止年度的财务业绩。该公司正在4：下午三点EST来讨论结果。

电话会议和网络广播详细信息

投资者可以在公司网站http://ir.arrowheadpharma.com/events.cfm上进行现场音频网络直播。对于希望参加电话会议的分析师，请拨打855-215-6159或315-625-6887，并提供会议编号6977547。

电话会议结束后约两小时，公司网站上将播放网络直播，并将保留90天。在通话结束后大约两个小时，音频重放也将可用，并将可用3天。要访问音频重播，请拨打855-859-2056或404-537-3406，并提供会议ID 6977547。

选定2017财年和最近的事件

2017年9月主办分析师研发日，以突出以下内容：
      靶向RNAi分子平台或TRiM™，利用配体介导的递送，并被设计成能够进行组织特异性靶向，同时在结构上简单
      TRiM™平台提供了几个潜在的竞争优势，包括：
         简化制造，降低成本
         多种给药途径（皮下，静脉内和吸入）
         加快临床应用
         广泛的安全边际
         将RNAi服用于肝脏以外的组织的承诺
      ARO-AAT是Arrowhead公司第二代皮下注射用于治疗α-1抗胰蛋白酶缺乏性肝病的临床候选药物，计划在2018年第一季度提交临床试验申请（CTA）
      ARO-HBV是Arrowhead第三代皮下注射临床候选药物，用于治疗慢性乙型肝炎病毒感染，计划于2018年第二季度完成CTA申请
      计划在2018年年底左右开始，箭头扩展的cardiometabolic管道，目前包括靶向载脂蛋白C-III的ARO-APOC3和靶向血管生成素样蛋白3（ANGPTL3）的ARO-ANG3
      TRiM™平台能够靶向以下程序所代表的肝外组织，包括肺和肿瘤：
         ARO-Lung1是第一个针对肺部未公开基因靶标的候选者，在啮齿类动物吸入给药后实现了近90％靶向敲除
         ARO-HIF2是Arrowhead公司的候选靶向肾细胞癌，在啮齿动物肿瘤模型中实现了85％的靶基因敲低
         CTA申请计划在2018年第四季度和2019年分别为ARO-Lung1和ARO-HIF2
在HEP DART 2017上展示了新的临床数据，展示了在2001年开放标签扩展研究中，在RNAi治疗后的50％的乙型肝炎患者中，HBV s-抗原降低了5.0 log10，持续的宿主反应，ARC-520
我们与安进公司的双产品心血管协作取得了持续的进展，其中之前称为ARO-LPA的针对目标脂蛋白（a）的一种已被正式提名为临床候选者，现在被Amgen称为AMG-890

2017财年年度财务结果选定

ARROWHEAD PHARMACEUTICALS，INC。
合并财务资料

截止到九月三十日

运行总结
2017 2016

收入$ 31,407,709 $ 158,333
营业费用
研究开发31,690,298 41,454,452
薪金和工资相关费用17,292,883 19,461,656
一般和行政费用6,838,402 9,940,737
股票薪酬7,891,595 11,595,816
折旧及摊销4,690,440 3,260,045
减值支出 - 2,050,817
或然代价 - 公平值调整 - （5,862,464）
全部经营费用68,403,618 81,901,059
经营亏损（36,995,909）（81,742,726）
其他收入╱（开支），所得税拨备2,615,614 19,724
净损失$（34,380,295）$（81,723,002）

每股净亏损（基本和稀释）：$（0.47）$（1.34）
加权平均股份数量73,898,598 61,050,880

财务状况摘要
9月30日，9月30日，
2017 2016
现金及现金等价物$ 24,838,567 $ 85,366,448
短期投资40,769,539 -
全部现金资源（现金和投资）65,608,106 85,366,448
其他资产38,414,174 42,410,057
总资产104,022,280 128,176,505
负债总额23,155,118 33,152,246
合计股东权益80,867，

作者: newchinabok 时间: 2017-12-13 13:57

皮下给药，效果如何？高不高效，观察之

作者: windu 时间: 2017-12-14 08:23

进度上一旦落后就很被动了，百舸争流，看看谁立潮头

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)